Documenting new cases of primary lung cancer diagnosed in 2020
Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020
This study looks at new cases of lung cancer diagnosed in 2020 to see how the disease and its treatment have changed over the years and to understand how many patients survive after one and five years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Collège des Pneumologues des Hôpitaux Généraux Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT04402099 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate and analyze changes in the epidemiology of primary lung cancer (PLC) over the last decade by documenting new cases diagnosed in respiratory medicine departments and lung cancer units at general hospitals in France during 2020. The primary endpoint is to estimate the 1-year and 5-year mortality rates for patients with PLC. Secondary endpoints include describing the patient population, diagnostic and therapeutic management, prognostic factors, and comparing these findings to previous studies conducted in 2000 and 2010. The study will provide valuable insights into the current state of PLC management and outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically or cytologically proven primary lung cancer diagnosed in 2020.
Not a fit: Patients with secondary lung cancer or those under 18 years of age will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of lung cancer trends and improve patient management strategies.
How similar studies have performed: Previous studies on lung cancer epidemiology have shown success in documenting trends and outcomes, making this approach a continuation of established research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020\* * Follow-up by a lung specialist at a General Hospital * Oral informed consent \* date of collected sample Exclusion Criteria: * Age \< 18 years * Secondary lung cancer * Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery * Previous enrolment in the study * Freedom deprived patient following a legal or administrative decision * Patient unable to give his(her) consent
Where this trial is running
Paris
- Collège des Pneumologues des Hôpitaux Généraux (CPHG) (General Hospital Pulmonologists College) — Paris, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.